Authors

• Ivo Planinc — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0003-0561-6704
• Dora Fabijanovic — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0003-2633-3439
• Boško Skoric — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0001-5979-2346
• Jana Ljubas Macek — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0001-7171-2206
• Hrvoje Jurin — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-2599-553X
• Jure Samardzic — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-9346-6402
• Zeljko Baricevic — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-5420-2324
• Hrvoje Gašparovic — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-2492-3702
• Maja Cikeš — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-4772-5549
• Davor Milicic — University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0001-9101-1570

Abstract

Purpose: There is a substantial amount of data demonstrating the influence of body mass index (BMI) on outcomes of patients after heart transplantation (HTx) or left ventricular assist device (LVAD) implantation. However, no direct comparisons were made between these two modalities of advanced heart failure treatment in a specific population in terms of pretreatment BMI. (1-3) Patients and Methods: We retrospectively studied 90 consecutive HTx (67 male, mean age 51.9±13, median follow-up 20.8 months) and 32 consecutive LVAD (27 male, mean age 58.3±8, mean follow-up 13.1 months) patients from our centre in the period from January 2010 to December 2014. The patients were categorized in groups according to pretreatment BMI: non-overweight patients (BMI 2 | 38 | 12 | | ≥25 kg/m2 | 52 | 20 | Figure 1. Kaplan-Meier survival curves for body mass index groups in relation to different treatment options. Figure 2. Modified Kaplan-Meier curves representing length of hospital stay for body mass index groups in relation to different treatment options. Conclusion: Non-overweight patients in our cohort demonstrated better survival with HTx than LVAD treatment. No influence of BMI on length of hospital stay was shown between the HTx and LVAD treatment groups.

Keywords

body mass index, heart transplantation, left ventricular assist device

DOI

Literature

1. Mohamedali B, Yost G, Bhat G Obesity as a risk factor for consideration for left ventricular assist devices. J Card Fail. 2015;10:800. DOI:. [Epub ahead of print]. https://doi.org/10.1016/j.cardfail.2015.06.006
2. Clark AL, Knosalla C, Birks E, Loebe M, Davos CH, Tsang S, et al. Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changes. Eur J Heart Fail. 2007;9(8):839–44. https://doi.org/10.1016/j.ejheart.2007.03.010
3. Butler J, Howser R, Portner PM, Pierson RN. Body mass index and outcomes after left ventricular assist device placement. Ann Thorac Surg. 2005;79(1):66–73. https://doi.org/10.1016/j.athoracsur.2004.06.047